contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
      researchContent {
        title
        lang
        pdfUrl
        relatedContent {
          __typename
          ...PublishingDetails
          ...Reactions
          id
        }
        content {
          title
          lang
          htmlBody
          publishedAt
          createdAt
          changedAt
          isOutdated
          isPremium
        }
      }
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


oriola-oyj-oriola-corporation-managers-transactions-westerlund-3

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

A new extensive report on Oriola is out today. The company updated its financial targets and segment structure in the spring, and we have naturally updated our report and views accordingly. In the big picture, however, this remains a waiting phase in the sense that the IT system investment will be completed in 2027 and the move to a new logistics and distribution center in Finland will take place in 2028. Efficiency benefits should eventually be realized from these. The associate company Kronans remains poorly profitable, and it cannot/will not be sold until profitability is in order. Thus, one will likely have to wait 2–3 years for all major drivers. At the same time, all of these naturally pose risks either operationally or, in the case of Kronans, to the balance sheet. However, the share price is affordable enough that we believe there is value here, but its unlocking may indeed take a while longer. It should also be mentioned that the company held a pre-silent call this morning, which in my opinion contained no significant news. The trends seen in Q1 (e.g., weakness in expert services, but strength in parallel imports and a lively Swedish market) have continued into Q2, and there should be no significant impacts from cost inflation as the company passes on the increase in logistics costs.                   Inderes              Oriola laaja raportti: Reseptinä kärsivällisyys - Inderes    Oriolan osake näyttää edulliselta, mutta sekä taseeseen että operatiiviseen toimintaan liittyy selkeitä riskeitä.

Another comment on Jussi Halme’s video regarding Oriola’s investments: A significant portion of this year’s Q1 sum of EUR 7.7 million went towards the land area for the Järvenpää logistics center. The “lead time” (paistoaika) for this is long, and thus it also burdens the result slightly on an annual basis. If I understand correctly, during the construction phase of the logistics center, SEB Leasing pays the capital costs to the contractor according to the agreement, and Oriola is responsible for paying the interest on that capital to SEB. Then, once the project is completed, Oriola pays leasing rent for the building. This is what capital efficiency means. Therefore, hundreds of millions of Oriola’s own capital will not be tied up in the project. How Oriola will operate two logistics centers in Finland simultaneously in 2027 will likely be a challenge for the company, not least from the perspective of IT systems.

Kronans Apotek AB: the turnaround this year is indeed a central question regarding the stock’s valuation. Perhaps a few observations: the merger was only completed last year, and this year attention can be shifted toward costs. From the perspective of IFRS 36 impairment testing, it is significant how the company management can convince the auditors of future cash flows. There is still a risk of write-downs, but much has already been recorded. At least for me, it has been a bit difficult to understand Oriola’s releases. According to the releases, Kronans Apotek has written down an extra amount of goodwill in 2024 and 2025. In reality, Swedish Pharmacy has written down those amounts under the balance sheet item Finansiella Anläggningstillgångar (Financial Non-current Assets) and Oriola then in its subsidiary shares. Kronans Apotek then has 554 MSEK of goodwill remaining on its own balance sheet for 2025, and it writes it down by approximately 110-115 MSEK annually. This is its own specific goodwill, with an amortization period of 20 years, of which five remain.

Quite valid points, largely the same issues I have raised regarding this myself. Coincidentally, I was just reviewing Oriola, so let’s include one image here that shows in a rather stark way how Kronans Apotek’s profitability has melted away, even though the 2022 merger should have brought synergies.

Let’s share this Jussi Halme video about Oriola here; the man usually talks a lot of sense. I haven’t had the chance to listen to it myself yet, but maybe it resonates with someone’s thoughts: https://www.youtube.com/watch?v=3orteSq7eXE

Rauli interviewed Oriola’s CFO Mats Danielsson    Topics: 00:00 Introduction  00:13 Mats Danielsson  01:28 Key points of the updated strategy  05:48 Changes in strategy  06:38 Financial targets  07:41 Growth target  09:19 Profitability target  13:44 Investments  15:01 Associated company Kronans Apotek  17:28 Equity ratio

Here are Rauli’s comments regarding Oriola’s Capital Markets Day yesterday.  Oriola already announced its new financial targets in connection with the Q1 results, which were presented yesterday at the Capital Markets Day. In our view, the targets rely heavily on the company’s IT system and warehouse investments, which will not be completed until 2027 and 2028. Thus, we believe the targeted efficiency and profit improvements will be weighted toward the end of the period lasting until 2029. Regarding the associate company Kronans, the company stated clearly that its profitability must improve before Oriola can consider selling its stake. This will still take several years, and we therefore do not expect a quick solution regarding Kronans.                   Inderes – 13 May 26              Oriolan CMD: Isompiin muutoksiin vielä pari vuotta - Inderes    Uskomme tehokkuus- ja tulosparannuksen painottuvan vuoteen 2029 asti kestävän kauden lopulle.

Oriola

Oriola Corporation Managers' transactions 30 April 2026 at 12:15 p.m. EESTOriola Corporation - Managers' transactions - Westerlund____________________________________________Person subject to...

<div class="abstract"></div>Oriola Corporation Managers' transactions 30 April 2026 at 12:15 p.m. EESTOriola Corporation - Managers' transactions - Westerlund____________________________________________Person subject to the notification requirementName: Westerlund, HeikkiPosition: Member of the Board/Deputy memberIssuer: Oriola CorporationLEI: 549300UWB1AIR85BM957Notification type: INITIAL NOTIFICATIONReference number: 549300UWB1AIR85BM957_20260429175858_263____________________________________________Transaction date: 2026-04-29Venue: XHELInstrument type: SHAREISIN: FI0009014351Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVETransaction details(1): Volume: 29893 Unit price: 0.00 EURAggregated transactions(1): Volume: 29893 Volume weighted average price: 0.00 EUR<div></div>

Oriola Oyj: Oriola Corporation - Managers' transactions - Westerlund

Oriola Oyj: Oriola Corporation - Managers' transactions - Westerlund